---
document_datetime: 2024-08-01 12:10:12
document_pages: 14
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/xofigo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: xofigo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 8.0702088
conversion_datetime: 2025-12-15 02:10:12.398281
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Xofigo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                    |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0054               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 30/07/2024                          |                                             | PL                               |                                                                                                                                                                            |
| R/0049               | Renewal of the marketing authorisation.                                                          | 20/07/2023                          | 15/09/2023                                  | PL                               | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Xofigo in the approved indication remains favourable and |

1 Notifications  are issued for  type I variations  and Article  61(3) notifications  (unless part of a group including a type II variation  or extension  application  or a worksharing  application).  Opinions are  issued for all  other procedures.

2 A Commission  decision  (CD) is issued for procedures  that affect  the terms of the marketing  authorisation  (e.g.  summary of  product characteristics,  annex  II, labelling,  package  leaflet).  The CD is issued within two  months of  the opinion  for variations  falling  under the scope of  Article  23.1a(a)  of Regulation  (EU) No.  712/2012, or within  one year  for other procedures.

3 SmPC  (Summary  of Product Characteristics),  Annex  II, Labelling,  PL (Package  Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |          | therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|---------------------------------------------------------------------------------------------|
| II/0052   | Submission of the final report from study 20702/DIRECT listed as a category 3 study in the RMP. This is a non-interventional drug utilisation study to investigate the risk of off-label use. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                      | 31/08/2023 | n/a        |          |                                                                                             |
| IB/0051   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                    | 04/05/2023 | 15/09/2023 | Annex II |                                                                                             |
| IA/0050/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 23/02/2023 | n/a        |          |                                                                                             |
| IB/0048   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                           | 15/02/2023 | n/a        |          |                                                                                             |

<div style=\"page-break-after: always\"></div>

| II/0047             | B.I.b.1.e - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a specification parameter which may have a significant effect on the overall quality of the AS and/or the FP                                                                                                                                                                   | 19/01/2023   | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SW/0045             | Post Authorisation Safety Study results - EMEA/H/C/PSR/S/0034 - Variation                                                                                                                                                                                                                                                                                                                                      | 14/10/2021   | 13/12/2021 | Annex II | The study results do not show an increase in the risk of death or cancer-specific death within the scope of the currently authorised therapeutic indication (third and later lines of therapy or in patients ineligible for any available systemic metastatic castration-resistant prostate cancer treatment). Therefore, in view of available data regarding the PASS final study report, the PRAC considered that removal of the condition of the marketing authorisation and respective changes to the Risk Management Plan were warranted. |
| PSUSA/10132 /202105 | Periodic Safety Update EU Single assessment - radium-223 dichloride                                                                                                                                                                                                                                                                                                                                            | 02/12/2021   | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0042/G           | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product | 02/09/2021   | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0041             | B.I.b.1.e - Change in the specification parameters and/or limits of an AS, starting                                                                                                                                                                                                                                                                                                                            | 02/09/2021   | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                     | material/intermediate/reagent - Deletion of a specification parameter which may have a significant effect on the overall quality of the AS and/or the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                 |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| IB/0043             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 25/05/2021 | n/a        |                 |                                   |
| PSUSA/10132 /202005 | Periodic Safety Update EU Single assessment - radium-223 dichloride                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 26/11/2020 | n/a        |                 | PRAC Recommendation - maintenance |
| IB/0039             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 24/04/2020 | 27/10/2020 | Annex II and PL |                                   |
| IA/0038/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - | 04/12/2019 | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

|                     | Replacement/addition of a site where batch control/testing takes place B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised                                  |            |            |             |                                                                               |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------|
| PSUSA/10132 /201905 | Periodic Safety Update EU Single assessment - radium-223 dichloride                                                                                                                                                                                  | 28/11/2019 | n/a        |             | PRAC Recommendation - maintenance                                             |
| II/0037             | B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products                                                       | 31/10/2019 | 27/10/2020 | SmPC and PL |                                                                               |
| II/0034             | B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product                                 | 17/01/2019 | n/a        |             |                                                                               |
| PSUSA/10132 /201805 | Periodic Safety Update EU Single assessment - radium-223 dichloride                                                                                                                                                                                  | 29/11/2018 | n/a        |             | PRAC Recommendation - maintenance                                             |
| IA/0035             | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                               | 01/10/2018 | n/a        |             |                                                                               |
| A20/0028            | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 30 November 2017 the opinion of the European Medicines Agency further to analyses of preliminary data of a clinical trial evaluating Xofigo in a patient | 26/07/2018 | 28/09/2018 | SmPC and PL | Please refer to the assessment report: Xofigo EMEA/H/A- 20/1459/C/002653/0028 |

<div style=\"page-break-after: always\"></div>

|         | population with asymptomatic or mildly symptomatic prostate cancer (ERA-223), found that the incidences of treatment emergent fractures and deaths were increased in the treatment arm (radium-223 dichloride plus abiraterone acetate and prednisone/prednisolone) compared to the control arm (placebo plus abiraterone acetate and prednisone/prednisolone). The CHMP was requested to assess the impact thereof on the benefit-risk balance of Xofigo and to give its recommendation whether the marketing authorisation of this product should be maintained, varied, suspended or revoked. As the request results from the evaluation of data resulting from pharmacovigilance activities, the CHMP opinion should be adopted on the basis of a recommendation of the Pharmacovigilance Risk Assessment Committee. The notification for the procedure is appended to this recommendation.   |            |            |             |                                                                                                                                                                                                                                                                                             |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0032 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 19/09/2018 | n/a        |             |                                                                                                                                                                                                                                                                                             |
| R/0030  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 26/04/2018 | 21/06/2018 | SmPC and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Xofigo in the approved indication remains favourable, but recommended that one additional five-year renewal be required based on the following pharmacovigilance grounds: |

<div style=\"page-break-after: always\"></div>

| • Results from  an ad-hoc analysis  of study 15396 (EudraCT 2013-003438-33) involving  the use of Xofigo  in combination  with abiraterone  and prednisone/prednisolone in patients with asymptomatic  or mildly  symptomatic metastatic  CRPC  indicated  that there may  be an increased incidence  of fractures  and deaths among  patients receiving Xofigo  in combination  with  abiraterone  acetate  and prednisone/prednisolone compared to patients receiving placebo  in combination  with abiraterone  acetate  and prednisone/prednisolone.  - At its November  2017 plenary,  PRAC  agreed  that a thorough evaluation  of the issue should be within  a procedure  under Article  20 of  Regulation  (EC) 726/2004. This procedure  has not concluded  but may result in the introduction  of specific  risk minimisation  measures  or an obligation  for  the MAH to undertake  a post-marketing  study to gather further safety  data that may impact on the benefit  risk balance  of  the product.  • At the March plenary  meeting  PRAC  agreed  that provisional  routine  risk minimisation  measures  in the form of updates to the product information  would  be necessary to minimise  the risks of fractures  and death associated  with the use of radium-223  dichloride  treatment initiated concurrently  with abiraterone  acetate  and prednisone/prednisolone treatment. These changes include amendments to sections  4.3, 4.4, and 5.1 of the SmPC. The PRAC  considered  that radium-223  dichloride  should be contraindicated  in combination  with  abiraterone  acetate and prednisone/prednisolone. Further warnings  and precautions  of use relating  to the risks of  fracture and death among patients  receiving  Xofigo  in combination  with abiraterone  acetate  and prednisone/prednisolone were  also   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                                  | included together with important information that the safety and efficacy of combination with second generation androgen receptor antagonists (e.g. enzalutamide) have not been established.                                                                                                                         |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0029             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                           | 14/06/2018 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                      |
| II/0031             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                           | 12/04/2018 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                      |
| II/0027             | B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions                                                                                                                                                                            | 30/11/2017 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                      |
| PSUSA/10132 /201705 | Periodic Safety Update EU Single assessment - radium-223 dichloride                                                                                                                                                                                                                                                                                                                     | 30/11/2017 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                    |
| PSUSA/10132 /201611 | Periodic Safety Update EU Single assessment - radium-223 dichloride                                                                                                                                                                                                                                                                                                                     | 22/06/2017 | 14/08/2017 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10132/201611.                                                                                                                                                                           |
| II/0025             | Update of sections 4.2, 5.1, 5.2, and 11 of the SmPC based on the update of the Xofigo Company Core Data Sheet (CCDS) to version 5.0. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.0 and to introduce non safety related editorial changes to | 22/06/2017 | 14/08/2017 | SmPC, Annex II, Labelling and PL | 5.1 Pharmacodynamic properties Pharmacodynamic effects Cardiac electrophysiology / QT prolongation No significant QTc prolonging effects were observed after intravenous injection of Xofigo in comparison with placebo in a subgroup of 29 patients in the phase III study (ALSYMPCA). Clinical efficacy and safety |

<div style=\"page-break-after: always\"></div>

|           | increase comprehensibility. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        | The primary efficacy endpoint was overall survival. Main secondary endpoints included time to symptomatic skeletal events (SSE), time to progression of total alkaline phosphatase (ALP), time to progression of prostate specific antigen (PSA), response to total ALP and normalisation of total ALP. 5.2 Pharmacokinetic properties At 10 minutes post injection, activity was observed in the bone and in the intestine. At 4 hours post injection, the mean percentage of the radioactive dose present in bone and intestine was approximately 61% and 49% respectively.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0022/G | This was an application for a group of variations. B.II.b.1.d - Replacement or addition of a manufacturing site for the FP - Site which requires an initial or product specific inspection B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation | 21/04/2017 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| T/0024    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 10/03/2017 | 03/04/2017 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| PSUSA/10132 /201605   | Periodic Safety Update EU Single assessment - radium-223 dichloride                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 01/12/2016   | n/a   | PRAC Recommendation - maintenance   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| IAIN/0021/G           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging                                                                                         | 25/10/2016   | n/a   |                                     |
| II/0014/G             | This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 21/07/2016   | n/a   |                                     |

<div style=\"page-break-after: always\"></div>

| N/0019              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                         | 21/06/2016   | 03/04/2017   | Labelling and PL   |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------|-----------------------------------|
| PSUSA/10132 /201511 | Periodic Safety Update EU Single assessment - radium-223 dichloride                                                                                                                                                                                                                                                                                                                                                                                                                                      | 09/06/2016   | n/a          |                    | PRAC Recommendation - maintenance |
| IAIN/0018/G         | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 30/05/2016   | 03/04/2017   | Annex II and PL    |                                   |
| II/0015             | B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP                                                                                                                                                                                                                                           | 01/04/2016   | n/a          |                    |                                   |
| PSUSA/10132 /201505 | Periodic Safety Update EU Single assessment - radium-223 dichloride                                                                                                                                                                                                                                                                                                                                                                                                                                      | 03/12/2015   | n/a          |                    | PRAC Recommendation - maintenance |
| IB/0013             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                   | 13/10/2015   | n/a          |                    |                                   |

<div style=\"page-break-after: always\"></div>

| II/0011             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                           | 23/07/2015   | 08/09/2015   | SmPC, Labelling and PL   |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------|
| PSUSA/10132 /201411 | Periodic Safety Update EU Single assessment - radium-223 dichloride                                                                                                                                                                                                                                                                                                                                                                                                                                         | 11/06/2015   | n/a          |                          | PRAC Recommendation - maintenance |
| IB/0010/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure | 29/04/2015   | n/a          |                          |                                   |
| IA/0008/G           | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor                                                                                                                 | 04/02/2015   | n/a          |                          |                                   |

<div style=\"page-break-after: always\"></div>

|             | changes to an approved test procedure B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                              |            |            |                 |                                   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| II/0007     | Replacement of the stopper material of the container closure system of Xofigo solution for injection. B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products                                                                                                                         | 22/01/2015 | 08/09/2015 | SmPC and PL     |                                   |
| PSUV/0005   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                     | 04/12/2014 | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0006/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 19/09/2014 | 08/09/2015 | Annex II and PL |                                   |
| IB/0004/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                         | 28/08/2014 | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

|           | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits   |            |            |    |                                   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| PSUV/0002 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                  | 13/06/2014 | n/a        |    | PRAC Recommendation - maintenance |
| N/0003    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                        | 11/04/2014 | 08/09/2015 | PL |                                   |
| II/0001   | To widen the limit for assay in the specification of the active substance. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                                                       | 20/02/2014 | n/a        |    |                                   |